Surrozen (NASDAQ:SRZN) Major Shareholder Purchases $91,365.10 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 5,266 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was acquired at an average price of $17.35 per share, with a total value of $91,365.10. Following the purchase, the insider directly owned 965,509 shares in the company, valued at approximately $16,751,581.15. This represents a 0.55% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Friday, December 5th, Group Gp Lp Column III purchased 30,884 shares of Surrozen stock. The shares were purchased at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The stock was acquired at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Stock Up 0.0%

Shares of SRZN stock traded up $0.01 on Monday, reaching $20.47. The company had a trading volume of 110,179 shares, compared to its average volume of 30,511. The stock has a market capitalization of $175.45 million, a PE ratio of -0.92 and a beta of 0.62. The business’s 50-day moving average is $13.90 and its 200 day moving average is $11.32. Surrozen, Inc. has a one year low of $5.90 and a one year high of $21.33.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The firm had revenue of $0.98 million during the quarter. On average, sell-side analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Stonepine Capital Management LLC boosted its stake in shares of Surrozen by 108.3% during the first quarter. Stonepine Capital Management LLC now owns 285,782 shares of the company’s stock valued at $3,332,000 after purchasing an additional 148,582 shares during the period. Heights Capital Management Inc. bought a new stake in Surrozen during the 1st quarter valued at $524,000. Driehaus Capital Management LLC purchased a new stake in Surrozen during the 1st quarter valued at $2,390,000. Nantahala Capital Management LLC boosted its position in Surrozen by 17.1% during the 1st quarter. Nantahala Capital Management LLC now owns 229,527 shares of the company’s stock valued at $2,676,000 after buying an additional 33,504 shares during the period. Finally, RA Capital Management L.P. grew its holdings in Surrozen by 140.3% in the 1st quarter. RA Capital Management L.P. now owns 679,130 shares of the company’s stock worth $7,919,000 after acquiring an additional 396,550 shares during the last quarter. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SRZN. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.50.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.